Preclinical disease and preventive strategies in IBD.
Hospital Beatriz Ângelo, Loures, Lisbon, Portugal.
Hospital Beatriz Ângelo, Loures, Lisbon, Portugal; Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: [email protected]
- Published Article
Current opinion in pharmacology
- Publication Date
Nov 19, 2020
There is growing evidence that inflammatory bowel disease has a preclinical phase that precedes disease symptoms, during which immune system activation has already occurred and inflammatory pathways have been primed, setting the stage for disease to expand and leading up to clinical diagnosis. Gaining insight to this pre-diagnosis period could improve our knowledge about disease pathogenesis and potentially result in the detection of biomarkers that could predict disease development. The ultimate goal of such research is to identify a population at risk for developing IBD, so preventive strategies could be implemented and disease prevention be achieved. Copyright © 2020 Elsevier Ltd. All rights reserved.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 12/04/2020 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/33221629